Skip to main content
. Author manuscript; available in PMC: 2022 Oct 5.
Published in final edited form as: Cell Rep. 2022 Jun 28;39(13):111012. doi: 10.1016/j.celrep.2022.111012

Figure 4. Polydatin treatment reduces omental metastases in vivo.

Figure 4.

(A) Schema for treatment.

(B) BLI was measured at baseline and prior to sacrifice using IVIS (n = 5 per cohort).

(C and D) Reduction in peritoneal metastases by polydatin treatment as measured by (C) IVIS imaging and (D) gross inspection of peritoneal tumor burden at necropsy.

(E) Overall tumor burden as measured as BLI on IVIS in polydatin and vehicle cohorts (**p < 0.01).

(F and G) Fluorescence imaging (F) and quantification (G) of omental metastases (*p < 0.05). All summary bar graphs represent mean ± SD.